Loading
A phase 1/2 trial of Lenalidomide, Dexamethasone, Daratumumab in multiple myeloma, run by AbbVie, now recruiting.
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations is a phase 1/2 interventional study registered as NCT06892522 by AbbVie, with 602 participants planned, started 2025-06-30 and due to reach its primary completion in 2035-12. Interventions recorded: Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Iberdomide, Carfilzomib, Daratumumab, Dexamethasone.
Shares Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone.
Shares Mezigdomide, Carfilzomib, Daratumumab, Dexamethasone.
Shares Daratumumab, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone, Multiple myeloma.
Shares Daratumumab, AbbVie (incl. ImmunoGen, Capstan), Lenalidomide, Dexamethasone.
Shares Mezigdomide, Carfilzomib, Dexamethasone, Multiple myeloma.
Shares Iberdomide, Lenalidomide, Dexamethasone, Multiple myeloma.
Shares Daratumumab, Lenalidomide, Dexamethasone, Multiple myeloma.